- Home
- RNAZ vs VINC Comparison
RNAZ vs VINC Comparison
Compare RNAZ & VINC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- VINC
- Stock Information
- Founded
- RNAZ 2016
- VINC 2019
- Country
- RNAZ United States
- VINC United States
- Employees
- RNAZ N/A
- VINC N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- VINC Biotechnology: Pharmaceutical Preparations
- Sector
- RNAZ Health Care
- VINC Health Care
- Exchange
- RNAZ Nasdaq
- VINC Nasdaq
- Market Cap
- RNAZ 7.2M
- VINC 6.2M
- IPO Year
- RNAZ 2021
- VINC N/A
- Fundamental
- Price
- RNAZ $8.08
- VINC $1.24
- Analyst Decision
- RNAZ Strong Buy
- VINC Buy
- Analyst Count
- RNAZ 1
- VINC 2
- Target Price
- RNAZ $20.00
- VINC $40.00
- AVG Volume (30 Days)
- RNAZ 4.3M
- VINC 1.1M
- Earning Date
- RNAZ 03-31-2025
- VINC 03-28-2025
- Dividend Yield
- RNAZ N/A
- VINC N/A
- EPS Growth
- RNAZ N/A
- VINC N/A
- EPS
- RNAZ N/A
- VINC N/A
- Revenue
- RNAZ N/A
- VINC N/A
- Revenue This Year
- RNAZ N/A
- VINC N/A
- Revenue Next Year
- RNAZ N/A
- VINC N/A
- P/E Ratio
- RNAZ N/A
- VINC N/A
- Revenue Growth
- RNAZ N/A
- VINC N/A
- 52 Week Low
- RNAZ $2.66
- VINC $1.18
- 52 Week High
- RNAZ $66.33
- VINC $187.44
- Technical
- Relative Strength Index (RSI)
- RNAZ 48.31
- VINC 28.95
- Support Level
- RNAZ $10.02
- VINC $1.18
- Resistance Level
- RNAZ $11.30
- VINC $1.38
- Average True Range (ATR)
- RNAZ 1.97
- VINC 0.11
- MACD
- RNAZ -0.18
- VINC 0.09
- Stochastic Oscillator
- RNAZ 26.75
- VINC 12.50
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
About VINC Vincerx Pharma Inc.
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.